YAQ006 and YAQ007 are, respectively, the intravenous and oral formulations of L-ornithine phenylacetate (L-OPA), a potent ammonia-scavenging agent. Yaqrit is preparing to start a phase 3 trial with ...

YAQ006 and YAQ007 are, respectively, the intravenous and oral formulations of L-ornithine phenylacetate (L-OPA), a potent ammonia-scavenging agent. Yaqrit is preparing to start a phase 3 trial with ...

LONDON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Yaqrit, a late clinical-stage company developing life-saving treatments for advanced liver disease, announced today that its recently acquired ammonia ...

High ammonia levels in the blood often indicate a problem with the liver. Doctors can provide treatment, including sodium benzoate and transplants. Learn more here.

PRINCETON, N.J., Sept. 26, 2022 /PRNewswire/ -- Fosun Pharma and MAIA Pharmaceuticals Jointly Announce the Successful Commercialization of Only FDA Approved 20ml Sodium Phenylacetate and Sodium ...

The pharmacokinetic profiles of phenylbutyrate and phenylacetate—a molecule formed in the metabolism of sodium phenylbutyrate—were similar. Buphenyl is taken with food.

Ornithine phenylacetate (OP) therapy did not lead to a significant difference in time to clinical improvement compared with placebo in patients with cirrhosis and hepatic encephalopathy (HE).